New Zealand multiple sclerosis (MS) patients will soon have affordable access to an additional option for the treatment of relapsing multiple sclerosis (MS) with news that PHARMAC will fund TECFIDERA® (dimethyl fumarate). To read more, click on the link below:
Tecfidera to be funded in New Zealand
Like this article?
Share on Facebook
Share on Twitter
Share on Linkdin
Share on Email